Tag Archives: SARs

Deadly Virus Flew From Canada To China On Commercial Flight

April 20, 2024 The Silo 2 Comments

Minister Says He Was Taken Aback After Learning Deadly Viruses Were Shipped From Winnipeg Lab to Wuhan

Report first published via friends at The Epoch Times

After learning that samples of deadly Ebola and Nipah viruses had been sent from Canada’s top-security lab in Winnipeg to China, Public Safety Minister Dominic LeBlanc said his reaction was similar to that of an MP who expressed incredulity upon learning of the move.

“I’m really concerned about the March 2019 incident where [Winnipeg lab scientists Xiangguo Qiu and Keding Cheng] were implicated in a shipment of live Ebola in Hanipah [Nipah] viruses on a commercial Air Canada flight. How the hell did that happen?” NDP MP Charlie Angus asked during a House of Commons Canada-China committee meeting on April 15.

In response, Mr. LeBlanc said, “When I saw that report, and publicly, I had the same reaction as you.”

A partly redacted national memo sent by the prime minister’s national security advisor to Prime Minister Justin Trudeau on June 29, 2017.

The minister deferred Mr. Angus’ question to the Public Health Agency of Canada, saying, “I don’t have any [information], but I had the same reaction as you, Mr. Angus.”

Mr. LeBlanc, who became minister of public safety in July 2023, was previously minister of intergovernmental affairs starting in July 2018.

The National Microbiology Laboratory (NML) in Winnipeg shipped 15 different strains of Nipah and Ebola viruses to the Wuhan Institute of Virology (WIV) in China on March 31, 2019. The package was sent from Winnipeg to Toronto and then on to Beijing via a commercial Air Canada flight.

Timeline: What Declassified Documents Reveal About the Fired Winnipeg Lab Scientists

Ms. Qiu and Mr. Cheng

The request to the NML management for the shipment of the viruses was facilitated by Ms. Qiu. The shipment was eventually approved by the NML management.

Ms. Qiu and Mr. Cheng, a married couple, were escorted out of the NML in July 2019 while under RCMP investigation. The couple were fired from their positions on Jan. 20, 2021, for having undisclosed ties to Chinese regime entities.

In 2021, in response to MPs’ questions about why the NML shipped virus samples to the Wuhan lab, laboratory management said the shipment followed all proper protocols and was in response to a letter from the Chinese lab indicating that they were to be used to understand their pathophysiology—the nature of infection—and the development of antivirals.

Declassified intelligence documents show that Ms. Qiu also sent antibodies and other materials to China without prior approval.

Shipments included antibodies for the China National Institute for Food and Drug Control, as well as small amounts sent to laboratories in the United Kingdom and the United States for testing.

The documents show that Ms. Qiu discussed the shipment of Ebola and Nipah with WIV employees in July 2018, and initially suggested that a formal agreement is not necessary as “no one owns the IP.” She also expressed “hope there is another way around” rather than issuing a formal agreement.

The documents also show that Ms. Qiu signed on to a project at WIV involving research on Ebola, and that some of the virus strains that were shipped from NML were meant for this project. Ms. Qiu had asked that the project remain a secret to her Canadian management as WIV was in the process of requesting the transfer of the virus strains from NML, the documents say.

Researchers work in the National Microbiology Laboratory in Winnipeg, Man., where the ZMapp antibody “cocktail” was created to fight Ebola. PHOTO BY HANDOUT

The Wuhan lab has been involved in synthetic biology research on the deadly Nipah virus, according to testimony from a U.S. scientist. Synthetic biology involves creating or redesigning biological entities and systems.

“The Nipah virus is a smaller virus than SARS2 [the virus causing COVID-19] and is much less transmissible,” Dr. Steven Quay, a Seattle-based physician-scientist, told a U.S. Senate subcommittee hearing on Aug. 3, 2022. “But it is one of the deadliest viruses, with a greater than 60 percent lethality” and 60 times deadlier than SARS2, he said. “This is the most dangerous research I have ever encountered.”

Chinese Talent Recruitment

During the April 15 House committee meeting, Mr. LeBlanc acknowledged revelations from the declassified documents that Ms. Qiu was involved in China’s Thousand Talents Program. The program was recognized by U.S. authorities as China’s efforts to “incentivize its members to steal foreign technologies needed to advance China’s national, military, and economic goals.”

It is clear that “elements from a Chinese-sponsored recruitment program were involved” at the Winnipeg lab, Mr. LeBlanc said. “It is well known that such programs are one way that China seeks to incentivize academics to participate in activities that exploit advancements in Canadian technologies.”

China is using the programs “to improve its military and intelligence capabilities, as well as the economic competitiveness all at the expense of Canada’s national interest,” the minister said.

He declined to address concerns raised by Conservative MP Michael Cooper regarding the delay in removing Ms. Qiu from the NML, saying it should be addressed to the health minister whose department is in charge of the Public Health Agency of Canada, which in turn oversees the NML.

Although concerns about the two were first raised in 2018, they weren’t fired until three years later. For The Silo, Andrew Chen. Omid Ghoreishi and Noé Chartier contributed to this report

Supplemental– Bio-warfare experts question why Canada was sending lethal viruses to China.

Supplemental- Canada sent untested ebola vaccine to World Health Organization.

Earth

COVID-19 Wildlife Connection

September 10, 2022 The Silo 2 Comments

With new cases of coronavirus (COVID-19) still being reported every day across the globe, we are starkly reminded that handling or coming into close contact with wildlife, their body parts, and excreta poses a risk of spillover of the pathogens [viruses, bacteria, parasites, and fungi] they host and maintain in nature, and to which we humans might be susceptible.

The illnesses animals spread to humans are known as zoonotic diseases, or zoonoses.

It is estimated that, globally, about one billion cases of human illness and millions of deaths occur every year from zoonoses. Some 60 percent of emerging infectious diseases that are reported globally are zoonoses and of the more than 30 new human pathogens detected in the last three decades, 75 percent have originated in animals.

A wide variety of vertebrates are carriers of zoonotic agents. Rodents, the most abundant mammal, also represent an abundant source of zoonotic diseases, carrying at least 180 unique zoonotic pathogens[1]. Because of their size, the ability to fly and their unique immune system, bats represent an important virus reservoir, though presently they are known to carry only about a third of the zoonotic pathogens that rodents do.

While there are fewer species of primates when compared to rodents and bats, a great proportion are zoonotic hosts. The risk that pathogens can infect humans increases with species more closely related to us. For example, the spillover of HIV to humans occurred from chimpanzees and sooty mangabeys, most likely through butchering and consumption of their meat. To date, HIV-AIDS has infected 75 million people and caused 32 million deaths[2].

Graphic design: Sarah Markes/WCS.

The persistent lethal capacity of zoonotic pathogens can also reside in its evolutionary strategies. Plague is a bacterial, vector-born disease transmitted by fleas from rodents –its natural reservoir– to humans and subsequently also from humans to humans that has impacted the history of mankind through multiple pandemics causing tens of millions of deaths worldwide. The responsible bacterial agent has evolved virulence factors that have allowed it to repeatedly and successfully evade the immune system of the mammalian host[3].

“Coming into close contact with wildlife — including their body parts and excreta — poses a risk of spillover of the pathogens they host, to which we humans might be susceptible.”

Zoonoses may exist in various forms: The most common, endemic zoonoses, are widespread in developing countries affect many people and animals and are by comparison mostly neglected by the international community, epidemic zoonoses vary widely in their duration and distribution and emerging and re-emerging zoonoses may or may not have occurred previously in a given population, but are generally observed to expand in new species, populations or areas.

Emerging infectious diseases (EIDs) and particularly zoonotic ones are a significant and growing threat to global health, global economy and global security. Analyses of their trends suggest that their frequency and economic impact are on the rise.

The conditions of so-called “wet markets” are ideal for incubating new diseases and bolster their transmission. Photo credit: Elizabeth L. Bennett/WCS

Recent examples of such emerging or re-emerging zoonoses include Rift Valley fever, severe acute respiratory syndrome (SARS), pandemic influenza, Yellow fever, Avian Influenza, West Nile virus, the Middle East respiratory syndrome coronavirus (MERS), and most recently COVID-19.

However, our current knowledge of zoonotic diseases and spillover mechanisms is still at its infancy. It is estimated that less than 0.1% of all viruses that may pose a threat to global health are now known to have been transmitted from animals to humans[4].

More than 300,000 viruses are estimated to await discovery in mammals, many of them bearing zoonotic potential. In the U.S.-funded PREDICT program, researchers estimate that there are more than 1.6 million unknown viral species in mammals and birds, 700,000 of which could pose a disease risk to humans, based on years of information gathering.

“In wet markets across the globe, live and dead animals — including many wildlife species — are sold for human consumption.”

Facing such a vast, unknown and unpredictable universe of zoonotic agents, we firmly believe that limiting the chances of contact between human and wild animals is the most effective way to reduce the risk of emergence of new zoonotic diseases.

In “wet markets” across the globe, live and dead animals — including many wildlife species — are sold for human consumption. In close quarters, a mix of saliva, blood, urine and other bodily fluids brush up against vendors and consumers alike. The conditions of these markets are ideal for incubating new diseases and bolster their transmission. They form one of the most detrimental bridges created by man over the natural barriers that previously separated humans and wild animals.

Destruction of nature is increasingly putting humans in contact with pathogens for which they have no natural immunity. Photo credit: Nick Hawkins

For example, in 2016, two officials from the Department of Livestock and Fisheries in Lao PDR, Drs. Bounlom Douangngeun and Watthana Theppangna along with One Health experts authored a paper which documented that wild mammals from 12 taxonomic families and capable of hosting 36 different known zoonotic pathogens were traded in only seven markets[5]. It is a similar situation that has enabled the emergence of the previously unknown SARS in central Guangdong Province in November 2002 and now COVID-19 coronavirus in Wuhan, China.

“Ignoring the danger posed by wildlife markets is a massive global public health liability for a healthy world.”

The interface within these wet markets has been largely ignored as a public health topic, but COVID-19 coronavirus has brought this interface back to the forefront and reminded us that ignoring the danger posed by wildlife markets is a massive global public health liability for a healthy world.

As Dr. Christian Walzer emphasized recently this is a “global health priority that cannot be ignored.” It is important to continue calling for three solutions to prevent this complex global challenge: close live animal markets that sell wildlife; strengthen efforts to combat trafficking of wild animals within countries and across borders; and work to change dangerous wildlife consumption behaviors, especially in cities.

For the Silo, Stephen Sautner- Executive Director of Communications, Wildlife Conservation Society- Bronx Zoo

NOTES

[1] Cleaveland et al. 2001. Diseases of humans and their domestic mammals: pathogen characteristics, host rage and the risk of emergence. Phil Trans R Soc Lond B 356, 991–999

[2] Huet T, Cheynier R, Meyerhans A. et al. « Genetic organization of a chimpanzee lentivirus related to HIV-1 » Nature 1990, 345;356–9.

Santiago ML, Range F, Keele BF, Li Y, Bailes E, Bibollet-Ruche F, Fruteau C, Noë R, Peeters M, Brookfield JF, Shaw GM, Sharp PM, Hahn BH (2005). “Simian Immunodeficiency Virus Infection in Free-Ranging Sooty Mangabeys (Cercocebus atys atys) from the Tai Forest, Cote d’Ivoire: Implications for the Origin of Epidemic Human Immunodeficiency Virus Type 2”. Journal of Virology. 79 (19): 12515–27.

https://www.unaids.org/en/resources/fact-sheet

[3] Demeure C.E., Dussurget O., Mas Fiol G., Le Guern A.-S., Savin C., & Pizarro-Cerda, J. 2019. Yersinia pestis and plague : an updated view on evolution, virulenvce determinants, immune subversion, vaccination and diagnostics. Genes & Immunity 20, 357–370.

[4] http://livescience.ecohealthalliance.org/predict/reports/2018-04-16-edi-measuring-viral-discovery.pdf

[5] Zoe F Greatorex & Sarah H Olson & Sinpakone Singhalath & Soubanh Silithammavong & Kongsy Khammavong & Amanda E Fine & Wendy Weisman & Bounlom Douangngeun & Watthana Theppangna & Lucy Keatts & Martin G, 2016. “Wildlife Trade and Human Health in Lao PDR: An Assessment of the Zoonotic Disease Risk in Markets,” PLOS ONE, Public Library of Science, vol. 11(3), pages 1–17, March.

Sci-Tech

Whole City COVID Testing Will Begin In Liverpool UK

November 12, 2020 The Silo 2 Comments

Pasadena, Calif. (November, 2020) – Innova Medical Group, Inc. (IMG) has partnered with the UK Government in its roll out of whole city screening and testing, beginning in Liverpool, with its INNOVA SARS-CoV-2 Antigen Rapid Qualitative Test Kits.

Innova Medical’s lateral flow antigen test uses nasal and throat swab samples to screen for infection, with highly accurate results in as little as 15-minutes. This test can be easily and safely administered anywhere, on both asymptomatic and symptomatic people, without costly delays and the need for a full-scale laboratory. With its low cost per test, about the same as a coffee and biscuit in London, at-risk populations and many with inequitable access to healthcare, can achieve peace-of-mind with a negative result. U.K. Government data showed the IMG rapid SARS-CoV-2 antigen test screened asymptomatic individuals with 98.98 percent accuracy.

https://youtu.be/S2qRibNrBPs

Dr. Susan Hopkins, Incident Director at Public Health England, said, “The tests we are using in Liverpool are accurate, especially in finding people who are infectious at that moment in time and so are more likely to pass it on to others. Part of the purpose of working with Liverpool to roll out whole city testing is to better understand how these tests work in the field, improve understanding of why people get tested, and the impact of this approach on reducing the transmission rate.”

Using the National Health Service (NHS COVID-19) app, people can book a test and later input their test results.

Individuals taking part in the roll out of Operation Moonshot will be notified of positive or negative results by text or email. With this important test-and-trace system in place, public health authorities can diagnose cases, isolate infected patients, trace their contacts, and implement stringent infection control policies to reduce outbreaks.

With colder months and the holiday season ahead, the risk of virus transmission accelerates with more indoor gatherings and travel. If people do not know they have COVID-19, it is unlikely they will take precautions to prevent virus spread. Research studies show that to achieve disease control both asymptomatic, people who are infected but never develop symptoms, and pre-symptomatic, infected people who develop symptoms later, must be isolated.

Under Operation Moonshot, the UK Government hopes to flatten the curve by employing proactive, rather than reactive, measures in its COVID-19 response. Up to 1-in-5 United Kingdom coronavirus infections present with no symptoms, but they are still contagious. The Centers for Disease Control and Prevention (CDC) says up to 40 percent of infected people are asymptomatic and should be tested if they have been exposed. Typically, a person develops symptoms 5 days after being infected; however, infectivity was found to be highest a day before symptom onset. After symptoms, such as a cough, fever, and shortness of breath, first appear, a person can remain contagious for at least ten days.

The Innova Rapid Antigen Test quickly identifies infectiousness. The lateral flow test can identify people with a high viral load who are the most likely to spread the virus. Daniel Elliott, President of Innova Medical Group, Inc., said, “Our lateral flow device incorporates a German nitrocellulose membrane partially composed of nanoparticles of colloidal gold. [ Colloidal gold is nanoparticles of gold in a liquid solution. These gold nanoparticles are coated in such a way that they detect Covid antibodies. CP ] This advanced, proprietary technology combined with our room temperature reagent, allows testing at point-of-care settings such as workplaces, universities, and airports.”

GLOBAL SUPPLY CHAIN AND PRODUCTION

Innova Medical Group Inc. offers a global supply chain including the innovative and respected firms, GE Healthcare (USA) and Sartorius (Germany). IMG secured exclusive manufacturing and distribution agreements for its best-in-class portfolio of screening and diagnostic tests. By the end of November 2020, IMG will produce millions of kits per day in its Brea, California plant, combined with activity from plants in other global locations. After being selected over a large number of submissions to take part in Operation Moonshot, IMG is also exploring options for production in the United Kingdom.

The Innova test carries a CE Marking indicating that this IVD device complies with the European In-Vitro Diagnostic Devices Directive (98/79/EC). This device may be legally commercialized in the European Union (EU). For the Silo, Julie R. Manley.

About Innova Medical Group

Innova Medical Group, Inc. (IMG), is a wholly-owned subsidiary of Pasaca Capital (Pasadena, Calif.). IMG strategically pivoted and leveraged its expertise in Healthcare and Medical Devices to create an ecosystem to respond to the COVID-19 pandemic. The Innova Medical Ecosystem is delivering millions of tests every day to satisfy the diverse, point-of-care requirements of the world’s governments, large corporations, and institutions. IMG offers a global supply chain including the innovative and respected firms, GE Healthcare (USA), and Sartorius (Germany). IMG secured exclusive manufacturing and distribution agreements for its best-in-class portfolio of screening and diagnostic tests. For more information, visit www.innovamedgroup.com.

Earth

Evaluation Of Practices Is Key For Lyme Disease Strategy

July 5, 2019 The Silo Leave a comment

Another year has ticked by and Lyme disease remains a problem across much of North America.

Over the years I have met with so many people – farmers, outdoor activists, friends, neighbours – who have come down with Lyme – so many, often young people, afflicted in the prime of their life.

Time and time again I am told our health care system seems unaware and unprepared to deal with what remains essentially a new and emerging infectious disease – a disease that mimics other ailments and all too often has flummoxed those not expert in tropical diseases or public health.

Compounding the problem is the confusing and somewhat dubious advice prevalent on social media.

We have government for a reason and to that end in 2015, I introduced legislation – a Private Member’s Bill – to mandate the Ontario Minister of Health to develop ‘A Provincial Framework and Action Plan Concerning Emerging Vector-Borne Diseases,’ to quote the title of the bill.

The bill passed second reading with all-party support and became the law of the land.

Given my previous background in both research and health, I felt bound to take a purely objective evidence and science-based approach to creating this legislation. I called for a provincial framework and an action plan through our Ministry of Health – a plan that, primarily, encompasses surveillance, education materials and guidelines – guidelines for prevention, identification, diagnosis, treatment and management, including emergency preparedness – and calls for the sharing of best practices provincially and across our country. It instructs the Minister of Health to bolster research collaboration among all concerned, particularly those in the public.

One of my goals is to facilitate an efficient, more effective allocation; essentially, of what I consider scarce health resources. Going back to prevention, it is much more cost-effective to prevent than to treat. We know that the worldwide cost of SARS, for example, was $40 billion, and the bill in Canada came in at $2 billion, so prevention is key. Prevention is certainly key when there is no vaccine or little in the way of effective treatment. When you are dealing with a particular affliction like Lyme, prevention is the only option.

A committee was struck because of my legislation, and three years after my bill passed, released recommendations in April 2018.

Their advice included a call for reviews of current tick surveillance activities; of current testing methodologies for diagnosing Lyme disease and other tick-borne illnesses; and a review of current clinical practice guidelines focussing on assessment, prevention and treatment.

The committee also, as in my legislation, calls for research, education and public awareness. It calls for improved communications to regulated health professionals regarding standards of practice for diagnosis and treatment, as well as, the provision of professional education, and a coordinated care model for patients at all stages of these diseases.

The spread of Lyme disease in Ontario is an important issue for the Ministry of Health.

Health Quality Ontario (HQO), in partnership with Public Health Ontario (PHO) and in collaboration with clinical experts, patients and caregivers across the province has developed a clinical guidance document for early-localized Lyme disease. HQO continues to review the evidence and has committed to making any necessary changes to the guidance document as the evidence warrants.

In my view, the Ministry of Health is making progress.

For the Silo, Toby Barrett -MPP for Haldimand-Norfolk.

Culture

Has SARS Prepared Ontario For Ebola Possibility?

October 15, 2014 The Silo Leave a comment

In October, 2014 Dr. Eric Hoskins, then Minister of Health and Long-Term Care, and Dr. David Mowat, Interim Chief Medical Officer of Health, issued the following statement on Ontario’s preparedness for Ebola virus disease in Ontario:

“We know that Ontarians may have concerns related to the ongoing challenges in West Africa and recent events in the United States regarding the spread of the Ebola virus.

Reason for concern: the Ebola Virus is almost biblical in nature with horrible effects on the inflicted.

Let us assure you that the safety of Ontario’s health care workers, patients and the public are our top priority.

We are confident that Ontario is prepared and ready to contain and treat any potential case of Ebola virus in our province — protocols are in place and we’ve seen the system work well in Ontario hospitals.

With the experience and lessons learned from the Severe Acute Respiratory Syndrome (SARS) epidemic, our health care facilities now have sophisticated infection control systems and procedures to protect health care providers, patients and all Ontarians. They are fully equipped to deal with any potential cases of Ebola.

Dr. Eric Hoskins, Minister of Health and Long-Term Care

But all health care workers, especially those providing care to patients, must be safe and protected. This is why we are working with health care employers to ensure they are providing appropriate training for their staff on the proper use of personal protective equipment and other occupational health and safety measures. We are also continuing to work with health care workers and employers to further strengthen protective measures and ensure they’re in place at all times.

Our health care workers are on the front lines and it is times like these when we are all reminded of how critical their work is in protecting the public. We want them to feel safe.

We will be reaching out to our health care partners to ensure they have the maximum protection possible and plan to release revised guidelines by the end of the week.

The government, in collaboration with our health system partners, is monitoring the Ebola situation and is continually assessing our state of readiness should a case of Ebola ever occur in Ontario.

On behalf of both the ministry and the government of Ontario, we would like to thank our health care workers for their selfless and tireless work on behalf of all Ontarians.”